Compare
Foghorn Therapeutics Inc. vs Verastem, Inc. vs Zomedica Corp. vs Bioharvest Sciences Inc.
| Latest fiscal year | Foghorn Therapeutics Inc. FHTX | Verastem, Inc. VSTM | Zomedica Corp. ZOMDF | Bioharvest Sciences Inc. BHST |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $30.91M | $30.91M | $32.03M | $34.51M |
| Revenue growth (YoY) | +36.8% | +209.1% | +17.4% | +37.0% |
| Gross margin | n/a | n/a | 67.7% | 59.3% (computed) |
| Operating margin | -279.5% | -550.3% | -263.4% | -16.2% |
| Net margin | -240.3% | -677.6% | -255.6% | -32.3% |
| Net income | -$74.28M | -$209.47M | -$81.86M | -$11.13M |
| EPS (Diluted) | -$1.18 | -$3.02 | -$0.08 | n/a |
| Operating cash flow | -$86.10M | -$137.51M | -$17.65M | -$7.23M |
| Free cash flow | -$86.15M | n/a | -$18.22M | -$9.58M |
| Cash & equivalents | $80.88M | $204.99M | $9.02M | $23.02M |
| Total assets | $198.10M | $246.44M | $127.04M | n/a |
| Total liabilities | $306.60M | $189.25M | $11.64M | n/a |
| Shareholders' equity | -$108.50M | $57.20M | $115.40M | $25.45M |
| Return on year-end equity | n/a | -366.2% | -70.9% | -43.8% |
| Shares outstanding | 56.66M | 77.74M | 979.95M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Foghorn Therapeutics Inc. | Verastem, Inc. | Zomedica Corp. | Bioharvest Sciences Inc. |
|---|---|---|---|---|
| Latest | $30.91M Ended 2025-12-31 | $30.91M Ended 2025-12-31 | $32.03M Ended 2025-12-31 | $34.51M Ended 2025-12-31 |
| 1 year earlier | $22.60M Ended 2024-12-31 | $10.00M Ended 2024-12-31 | $27.29M Ended 2024-12-31 | $25.19M Ended 2024-12-31 |
| 2 years earlier | $34.16M Ended 2023-12-31 | n/a | $25.19M Ended 2023-12-31 | $12.67M Ended 2023-12-31 |
| 3 years earlier | $19.23M Ended 2022-12-31 | $2.60M Ended 2022-12-31 | $18.93M Ended 2022-12-31 | n/a |
| 4 years earlier | $1.32M Ended 2021-12-31 | $2.05M Ended 2021-12-31 | $4.13M Ended 2021-12-31 | n/a |